Pharmacoeconomical evaluation of combination therapy for lifetime hypertension treatment in Japan

Japan Medical Association Journal

Volumn 48, Issue 12, 2005, Pages 574-585

  Saito, Ikuo ^a   Kobayashi, Makoto ^b   Matsushita, Yasuyuki ^c,d   Saruta, Takao ^e  

^a KEIO UNIVERSITY   (Japan)

^b Crecon Research and Consulting Inc   (Japan)

^c TOKYO UNIVERSITY OF SCIENCE   (Japan)

^d DAIICHI SANKYO CO   (Japan)

^e KEIO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Antihypertensives; Cardiovascular disease; Combination therapy; Cost effectiveness analysis; Essential hypertension

Indexed keywords

ANGIOTENSIN 2 RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; AZELNIDIPINE; CALCIUM ANTAGONIST; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; OLMESARTAN; TRICHLORMETHIAZIDE;

ADULT; ANTIHYPERTENSIVE THERAPY; ARTICLE; BLOOD PRESSURE REGULATION; CARDIOVASCULAR DISEASE; CHRONIC KIDNEY FAILURE; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DIABETES MELLITUS; DISEASE SEVERITY; DRUG COST; ECONOMIC EVALUATION; ESSENTIAL HYPERTENSION; FEMALE; HUMAN; JAPAN; LONG TERM CARE; MALE; MICROALBUMINURIA; PRACTICE GUIDELINE; PROBABILITY; RENAL PROTECTION; SENSITIVITY ANALYSIS; SURVIVAL RATE;

EID: 33644518391     PISSN: 13468650     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (43)

1. Collins R, MacMahon S. Blood pressure, antihypertensive drug treatment and the risks of stroke and of coronary heart disease. Br Med Bull. 1994;50:272-298.
2. Blood Pressure Lowering Treatment Trialists' Collaboration. Effects of different blood-pressure-lowering regimens on major cardiovascular events: results of prospectively designed overviews of randomised trials. Lancet. 2003;362:1527-1535.
3. Staessen JA, Wang JG, Thijs L. Cardiovascular prevention and blood pressure reduction: a quantitative overview updated until 1 March 2003. J Hypertens. 2003;21:1055-1076.
4. Chobanian AV, Bakris GL, Black HR, et al. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. The JNC 7 Report. JAMA. 2003;289:2560-2572.
5. World Health Organization, International Society of Hypertension Writing Group. 2003 World Health Organization (WHO)/International Society of Hypertension (ISH) statement on management of hypertension. J Hypertens. 2003;21:1983-1992.
6. Guidelines Committee. 2003 European Society of Hypertension/European Society of Cardiology guidelines for the management of arterial hypertension. J Hypertens. 2003;21:1011-1053.
7. Williams B, Poulter NR, Brown MJ, et al. British Hypertension Society guidelines for hypertension management 2004 (BHS-IV): Summary. Br Med J. 2004;328:634-640.
8. Japanese Society of Hypertension Subcommittee for the Management of Hypertension: Guidelines for the management of hypertension for general practitioners. Hypertens Res. 2001; 24:613-634.
9. Verdecchia P, Reboldi G, Angeli F, et al. Adverse prognostic significance of new diabetes in treated hypertensive subjects. Hypertension. 2004;43:963-969.
10. Saito I, Kobayashi K, Saruta T. Economic analysis of antihypertensive agents in treating patients with essential hypertension. J Clin Therap Med. 2003;19:777-788. (in Japanese)
11. Ikeda S, Kobayashi M. Prediction of long-term prognosis for diabetes patients. Development of risk simulation soft for costs-effectiveness analysis. In: Bunshi Tounyoubyougaku no Shinpo 2003. Tokyo: Kanehara Shuppan; 2003:191-194. (in Japanese)
12. Shichiri M, Kishikawa H, Ohkubo Y, Wake N. Long-term results of the Kumamoto Study on optimal diabetes control in type 2 diabetic patients. Diabetes Care. 2000;23(Suppl 2):B21-29.
13. Nakai S, Shinzato T. An overview of diabetic nephropathy dialysis patients in Japan - Based on the results of annual survey of Japanese Society for Dialysis Therapy. Jpn J Clin Dialysis. 2001;17:59-64. (in Japanese)
14. Anderson KM, Odell PM, Wilson PWF, Kannel WB. Cardiovascular disease risk profiles. Am Heart J. 1991;121:293-298.
15. WHO Monthly Database. Available at: http://www3.who.int/whosis/menu.cfm?path=mort. Accessed 17 August 2004.
16. Yoshinaga K, Iimura O, Abe K, et al. A multicenter double-blind comparison study of CS-905 (azelnidipine) with nitrendipine in patients with essential hypertension. J Clin Therap Med. 2000; 16:671-739. (in Japanese)
17. 1 receptor antagonist, compared with enalapril maleate in patients with mild-to-moderate essential hypertension. Clin Therap Med. 2004;20:115-159. (in Japanese)
18. National Intervention Cooperative Study in Elderly Hypertensives Study Group. Randomized double-blind comparison of a calcium antagonist and a diuretic in elderly hypertensives. Hypertension. 1999;34:1129-1133.
19. Conlin PR, Gerth WC, Fox J, Roehm JB, Boccuzzi SJ. Four-year persistence patterns among patients initiating therapy with the angiotensin II receptor antagonist losartan versus other antihypertensive drug classes. Clin Ther. 2001;23:1999-2010.
20. Saito I, Saruta T. Effect of education through a periodic newsletter on persistence with antihypertensive therapy. Hypertens Res. 2003;26:159-162.
21. The ALLHAT Collaborative Research Group. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA. 2002;288:2981-2997.
22. Julius S, Kjeldsen SE, Weber M, et al. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial. Lancet. 2004;363:2022-2031.
23. Heart Outcomes Prevention Evaluation (HOPE) Study Investigators. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Lancet. 2000;355:253-259.
24. Parving HH, Lehnert HL, Mortensen JB, Gomis R, Andersen S, Arner P. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med. 2001;345:870-878.
25. Brenner BM, Cooper ME, Zeeuw DD, et al. for the RENAAL Study Investigators. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med. 2001;345:861-869.
26. Furukawa T, Kato T, Hayashi R. Efficacy and adverse drug reaction of diuretics. Nippon Rinsho. 1974;32:2650-2658. (in Japanese)
27. Hokenyaku Jiten. Tokyo: Yakugyo Jiho; Apr. 2004. (in Japanese)
28. Lipscomb J, Weinstein MC, Torrance GW. Time preference. In: Gold MR, Seigel JE, Russell LB, Weinstein MC ed, Cost-Effectiveness in Health and Medicine. New York: Oxford University Press; 1996:214-246.
29. Tuomilehto J, Rastenyte D, Birkenhager WH, et al. Effects of calcium-channel blockade in older patients with diabetes and systolic hypertension. N Engl J Med. 1999;340:677-684.
30. Iwashita M, Matsushita Y, Sasaki J, Arakawa K, Kono S. Relation of serum total cholesterol and other risk factors to risk of coronary events in middle-aged and elderly Japanese men with hypercholesterolemia. The Kyushu Lipid Intervention Study. Circ J. 2004;68:405-409.
31. Suzuki K. The characteristics of stroke in Japan. Prev Gerontol. 2002;1:16-22. (in Japanese)
32. Statistics and Information Department, Minister's Secretariat, Ministry of Health, Labour and Welfare. Abridged Life Tables for Japan. Tokyo: Health and Welfare Statistics Association; 2003. (in Japanese)
33. Statistics and Information Department, Minister's Secretariat, Ministry of Health, Labour and Welfare. National Medical Care Expenditure Estimates. Tokyo: Health and Welfare Statistics Association; 2003. (in Japanese)
34. Chrysant SG, Marbury TC, Robinson TD. Antihypertensive efficacy and safety of olmesartan medoxomil compared with amlodipine for mild-to-moderate hypertension. J Hum Hypertens. 2003;17:425-432.
35. Kuwajima I, Kuramoto K, Ogihara T, et al. Tolerability and safety of a calcium channel blocker in comparison with a diuretic in the treatment of elderly patients with hypertension: secondary analysis of the NICS-EH. Hypertens Res. 2001;24:475-480.
36. Kinjo K, Kimura Y, Shinzato Y, et al. An epidemiological analysis of cardiovascular diseases in Okinawa, Japan. Hypertens Res. 1992;15:111-119.
37. Fujiwara T, Nishimura T, Ohkuko T, et al. Rationale and design of HOMED-BP study: Hypertension objective treatment based on measurement by electrical devices of blood pressure study. Blood Press Monit. 2002;7:77-82.
38. Fukui T, Rahman M, Hayashi K, et al. Candesartan Antihypertensive Survival Evaluation in Japan (CASE-J) trial of cardiovascular events in high-risk hypertensive patients: rationale, design, and methods. Hypertens Res. 2003;26:979-990.
39. Kuramoto K, Ichikawa S, Hirai A, Kanada S, Nakachi T, Ogihara T. Azelnidipine and amlodipine: a comparison of their pharmacokinetics and effects on ambulatory blood pressure. Hypertens Res. 2003;26:201-208.
40. Baba S for the J-MIND Study Group. Nifedipine and enalapril equally reduce the progression of nephropathy in hypertensive type 2 diabetics. Diabetes Res Clin Pract. 2001;54:191-201.
41. Kumagai H, Hayashi K, Kumamaru H, Saruta T. Amlodipine is comparable to angiotensin-converting enzyme inhibitor for long-term renoprotection in hypertensive patients with renal dysfunction: a one-year, prospective, randomized study. Am J Hypertens. 2000;13:980-985.
42. Hayashi K, Kumagi H, Saruta T. Effect of efonidipine and ACE inhibitor on proteinuria in human hypertension with renal impairment. Am J Hypertens. 2003;16:116-122.
43. Lewis EJ, Hunsicker LG., Clarke WR, et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med. 2001;345: 851-860.